KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Debt to Equity (2016 - 2026)

Emergent BioSolutions has reported Debt to Equity over the past 17 years, most recently at $1.1 for Q1 2026.

  • For Q1 2026, Debt to Equity fell 8.96% year-over-year to $1.1; the TTM value through Mar 2026 reached $1.1, down 8.96%, while the annual FY2025 figure was $1.09, 20.37% down from the prior year.
  • Debt to Equity for Q1 2026 was $1.1 at Emergent BioSolutions, roughly flat from $1.09 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.37 in Q4 2024 and troughed at $0.32 in Q4 2022.
  • A 5-year average of $0.86 and a median of $0.72 in 2022 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: tumbled 35.65% in 2022 and later soared 147.36% in 2024.
  • Year by year, Debt to Equity stood at $0.32 in 2022, then surged by 112.77% to $0.69 in 2023, then soared by 99.91% to $1.37 in 2024, then decreased by 20.37% to $1.09 in 2025, then grew by 0.17% to $1.1 in 2026.
  • Business Quant data shows Debt to Equity for EBS at $1.1 in Q1 2026, $1.09 in Q4 2025, and $1.14 in Q3 2025.